Iambic Therapeutics

IAMNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$758.887 M

$16.01 -2.02%

Close of 21 Oct 2026

As of 21 Oct 2026, Iambic Therapeutics (IAM) has a market capitalization of $758.9M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 162 →

#49Odyssey TherapeuticsODTX$912.6M
#50SL ScienceSLBT$841.1M
#51Iambic TherapeuticsIAM$758.9M
#524D Molecular TherapeuticsFDMT$723.7M
#53Prime MedicinePRME$711.0M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Iambic Therapeutics, worth $11.5M. Grants and option exercises are excluded.

Evan Lockwood Rachlin$11.5M
718,750 shares at $16.00 on 16 Oct 2026 · filed 19 Oct 2026

What if Iambic Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.6T

$603,860.42

Per share 37,718× higher

Bitcoin $1.69T

$35,699.87

Per share 2,230× higher

Nvidia $5.22T

$110,059.90

Per share 6,874× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Iambic Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Oct 2026. Read the methodology.